Results from VIT-0910: temozolomide plus vincristine and irinotecan in refractory rhabdomyosarcoma

Julia Chisholm, PhD, FRCPCH, The Royal Marsden NHS Foundation Trust, describes the VIT-0910 study, a European randomized Phase II trial, in which efficacy and safety of vincristine and irinotecan combination therapy with or without temozolomide was assessed in patients with relapsed or refractory rhabdomyosarcoma. Results suggest that the addition of temozolomide improved the efficacy of chemotherapy in patients with relapsed rhabdomyosarcoma, with vincristine, irinotecan, and temozolomide together being considered as standard treatment going forward. Dr Chisholm also explains that the addition of regorafenib, a tyrosine kinase inhibitor, to vincristine and irinotecan combination therapy is also being investigated in an ongoing study, with promising results obtained from a Phase I trial. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).